Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News NHS under fire for rationing hep C drugs NHS England tried to interfere with NICE appraisals, says BMJ.
US Gilead hopes cut-price pan-genomic hep C combo will revive s... Epclusa is first treatment for all six major virus genotypes.
News EU regulators back new Hep C combo pills Two new hepatitis C combination drugs from Gilead and Merck Sharp and Dohme (MSD), that negate the need for interferon therapy and its hated side effects, have been recommended for approval
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.